The Future Is Inside Your Head
Neuralink implanted its first human brain-computer interface (BCI) in early 2024. Two years later, the results from clinical trials are both remarkable and sobering. The technology works — paralyzed patients can control computers, phones, and robotic arms with their thoughts. But the gap between "working BCI" and "consumer brain chip" is enormous, and the ethical questions are only getting harder.
What Works
Neuralink's N1 implant has demonstrated: cursor control on screens (patients can browse the web, play chess, write messages), control of external devices (robotic arms, computer interfaces), and communication for patients who've lost the ability to speak. For people with severe paralysis, spinal cord injuries, and ALS, Neuralink is genuinely life-changing.
What Doesn't Work (Yet)
The consumer vision — cognitive enhancement, memory augmentation, brain-to-brain communication, "downloading knowledge" — is science fiction for now. Current BCIs read brain signals; they don't write to the brain. The bandwidth is limited (imagine typing at 30 words per minute with your thoughts vs. 80+ WPM with your fingers). And the surgical implantation process carries real risks.
The Ethics Debate
For medical use (helping paralyzed patients), the ethical case is strong — the benefits clearly outweigh the risks. But Neuralink's stated long-term goal is cognitive enhancement for healthy humans. This raises questions about: cognitive inequality (will rich people literally be smarter?), data privacy (who owns your thoughts?), security (can brain implants be hacked?), and identity (does a modified brain change who you are?).
The Investment Angle
Neuralink is private. The BCI industry is investable through: Medtronic (MDT) — deep brain stimulation leader, Blackrock Neurotech — BCI competitor, and broad AI/biotech ETFs. The commercial BCI market is projected to reach $6 billion by 2030.
